Danaher Corporation $DHR Shares Sold by Nations Financial Group Inc. IA ADV

Key Points

• Nations Financial Group Inc. IA ADV reduced its stake in Danaher Corporation by 33.6%, selling 2,711 shares and holding 5,351 shares valued at $1,097,000 at the end of the first quarter.
• Numerous hedge funds have adjusted their positions in Danaher, with Fayez Sarofim & Co increasing their stake by 0.6% and Coastal Bridge Advisors LLC expanding theirs by 4.8% in the last quarter.
• Danaher reported earnings of $1.80 per share for the quarter, exceeding analysts' expectations, with revenue of $5.94 billion, which is a 3.4% increase from the previous year.

Nations Financial Group Inc. IA ADV decreased its holdings in shares of Danaher Corporation (NYSE:DHR - Free Report) by 33.6% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,351 shares of the conglomerate's stock after selling 2,711 shares during the period. Nations Financial Group Inc. IA ADV's holdings in Danaher were worth $1,097,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the company. Fayez Sarofim & Co grew its stake in Danaher by 0.6% during the fourth quarter. Fayez Sarofim & Co now owns 8,287 shares of the conglomerate's stock valued at $1,902,000 after acquiring an additional 50 shares in the last quarter. Coastal Bridge Advisors LLC boosted its holdings in shares of Danaher by 4.8% during the 4th quarter. Coastal Bridge Advisors LLC now owns 1,099 shares of the conglomerate's stock valued at $252,000 after purchasing an additional 50 shares during the last quarter. MGO One Seven LLC boosted its holdings in shares of Danaher by 1.3% during the 4th quarter. MGO One Seven LLC now owns 4,285 shares of the conglomerate's stock valued at $984,000 after purchasing an additional 53 shares during the last quarter. Hills Bank & Trust Co boosted its holdings in shares of Danaher by 0.3% during the 1st quarter. Hills Bank & Trust Co now owns 18,015 shares of the conglomerate's stock valued at $3,693,000 after purchasing an additional 53 shares during the last quarter. Finally, Sageworth Trust Co boosted its holdings in shares of Danaher by 2.3% during the 1st quarter. Sageworth Trust Co now owns 2,404 shares of the conglomerate's stock valued at $493,000 after purchasing an additional 54 shares during the last quarter. Institutional investors own 79.05% of the company's stock.

Danaher Stock Up 3.7%

Shares of DHR traded up $7.4660 during mid-day trading on Friday, hitting $211.3660. The company's stock had a trading volume of 1,340,345 shares, compared to its average volume of 4,210,182. The company's 50-day moving average is $200.45 and its 200-day moving average is $199.55. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $279.90. The firm has a market capitalization of $151.35 billion, a price-to-earnings ratio of 44.97, a PEG ratio of 2.95 and a beta of 0.73. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, topping the consensus estimate of $1.64 by $0.16. The firm had revenue of $5.94 billion during the quarter, compared to analyst estimates of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. Danaher's revenue was up 3.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, equities research analysts forecast that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Analysts Set New Price Targets

DHR has been the subject of several research reports. Barclays reissued an "overweight" rating and set a $225.00 price objective (up previously from $215.00) on shares of Danaher in a report on Tuesday, June 24th. HSBC dropped their price objective on shares of Danaher from $270.00 to $240.00 in a report on Friday, April 25th. UBS Group dropped their price objective on shares of Danaher from $240.00 to $225.00 and set a "buy" rating for the company in a report on Wednesday, July 23rd. Wells Fargo & Company reduced their target price on shares of Danaher from $210.00 to $205.00 and set an "equal weight" rating on the stock in a report on Wednesday, July 23rd. Finally, Robert W. Baird boosted their target price on shares of Danaher from $225.00 to $226.00 and gave the stock an "outperform" rating in a report on Friday, July 18th. Seventeen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $247.61.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.